Bavarian Nordic A/S BVNKF:OTCPK

RT Quote | Exchange | USD
Last | 02/19/21 EST
39.30UNCH (UNCH)
52 week range
15.89 - 39.30

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close39.30
  • 52 Week High39.30
  • 52 Week High Date02/19/21
  • 52 Week Low15.89
  • 52 Week Low Date04/21/20
  • Market Cap2,304.89M
  • Shares Out58.41M
  • 10 Day Average Volume100
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)2.23
  • P/E (TTM)17.62
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/12/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Bavarian Nordic A/S News

There is no recent news for this security.

Latest BVNKF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2...
Gerard van Odijk M.D.
Chairman
Anders Pedersen M.D., Ph.D.
Vice Chairman
Paul Chaplin Ph.D.
President
Henrik Birk
Chief Operating Officer
Henrik Juuel
Chief Financial Officer
Jean-Christophe May
Executive Vice President
Address
Philip Heymans Alle 3
Hellerup
2900
Denmark